Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

P-011

Supelco

(+)-Propoxyphene solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C22H29NO2
Numéro CAS:
Poids moléculaire :
339.47
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

Concentration

1.0 mg/mL in acetonitrile

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

forensics and toxicology

Format

single component solution

Température de stockage

2-8°C

Chaîne SMILES 

CCC(=O)O[C@@](Cc1ccccc1)([C@H](C)CN(C)C)c2ccccc2

InChI

1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1

Clé InChI

XLMALTXPSGQGBX-GCJKJVERSA-N

Informations sur le gène

human ... OPRM1(4988)

Description générale

A certified Snap-N-Spike® solution standard suitable for propoxyphene testing methods by GC/MS or LC/MS in pain prescription monitoring, clinical toxicology, urine drug testing, or forensic analysis. Propoxyphene, also known as dextropropoxyphene, is an opioid analgesic drug intended for treatment of mild pain. In combination with either paracetamol or aspirin, dextropropoxyphene is sold under trade names including Darvocet-N® and Darvon®.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Darvocet-N is a registered trademark of AAIPharma LLC
Darvon is a registered trademark of Xanodyne Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameExclamation mark

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

35.6 °F - closed cup

Point d'éclair (°C)

2 °C - closed cup


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Suicides involving co-proxamol fell dramatically after withdrawal in UK.
Zosia Kmietowicz
BMJ (Clinical research ed.), 344, e3255-e3255 (2012-05-11)
Margareeta Häkkinen et al.
Forensic science international, 222(1-3), 327-331 (2012-08-14)
There is a rising trend of fatal poisonings due to medicinal opioids in several countries. The present study evaluates the drug and alcohol findings as well as the cause and manner of death in opioid-related post-mortem cases in Finland from
W Stephen Waring et al.
Clinical toxicology (Philadelphia, Pa.), 49(6), 452-456 (2011-08-10)
The Medicines and Healthcare products Regulatory Authority (MHRA) is the government body with responsibility for regulating new and existing medicines and medical devices in the United Kingdom. The Yellow Card scheme is a well-established pharmacovigilance system that collects voluntary reports
Robert B Raffa et al.
Expert opinion on pharmacotherapy, 13(10), 1397-1409 (2012-05-10)
d-Propoxyphene, which was previously available in many single-agent and combination products, was recently voluntarily withdrawn from the US market following an FDA recommendation based partly on the concern that the risk associated with QT prolongation exceeded the clinical benefit of
Yatan Pal Singh Balhara et al.
Journal of opioid management, 8(1), 45-49 (2012-04-07)
In view of increasing safety concerns, there is a need to assess benefits of use of dextropropoxyphene as opioid substitution treatment, if any. This study aims at urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique